title: Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies.
abstract: OBJECTIVE
  The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review- At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were proposed. Increased utilization of mechanical devices for intra-arterial recanalization can be achieved by obtaining more definitive evidence of efficacy in randomized clinical trials, identification of patient characteristics associated with treatment efficacy, optimization of technical approaches, clarification of effective time windows, and development of approaches to limit complications. Neuroprotective strategies remain viable; recommendations for further study of these agents include an emphasis on rapid administration, consideration of the systemic effects of ischemic stroke, prevention of complications associated with early reperfusion, a focus on agents with multiple mechanisms of action, and consideration of possible interactions between neuroprotective and thrombolytic therapies.
  
  
  CONCLUSIONS
  Extending intravenous thrombolysis to a broader patient population, clarifying the risk and benefits of intra-arterial reperfusion therapies, and further development of neuroprotective therapies were the key recommendations from STAIR VII.
authors.affiliation: Stanford Stroke Center, 780 Welch Road, Suite 205, Palo Alto, CA 94304, USA. albers@stanford.edu
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Albers
authors.forename: Larry B
authors.initials: LB
authors.lastname: Goldstein
authors.forename: David C
authors.initials: DC
authors.lastname: Hess
authors.forename: Lawrence R
authors.initials: LR
authors.lastname: Wechsler
authors.forename: Karen L
authors.initials: KL
authors.lastname: Furie
authors.forename: Philip B
authors.initials: PB
authors.lastname: Gorelick
authors.forename: Patty
authors.initials: P
authors.lastname: Hurn
authors.forename: David S
authors.initials: DS
authors.lastname: Liebeskind
authors.forename: Raul G
authors.initials: RG
authors.lastname: Nogueira
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Saver
mesh_terms: D002545:Brain Ischemia / Q000628:therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents; D018696:Neuroprotective Agents